Cerus Corporation is developing medical products based on a platformtechnology that prevents nucleic acid replication. The company's initialapplication of this technology is the development of systems to inactivateviruses, bacteria and other pathogens in blood components used for transfusion. The company is also focusing research and development efforts on other potential health care applications for this platform technology, including pathogen inactivation of source plasma used for fractionation, improving the outcomes of stem cell transplantation.
| Revenue (Most Recent Fiscal Year) | $180.27M |
| Net Income (Most Recent Fiscal Year) | $-20.92M |
| PE Ratio (Current Year Earnings Estimate) | -- |
| PE Ratio (Trailing 12 Months) | -- |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | 1.36 |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 4.49 |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | -- |
| Pre-Tax Margin (Trailing 12 Months) | -10.15% |
| Net Margin (Trailing 12 Months) | -10.23% |
| Return on Equity (Trailing 12 Months) | -34.81% |
| Return on Assets (Trailing 12 Months) | -9.68% |
| Current Ratio (Most Recent Fiscal Quarter) | 2.32 |
| Quick Ratio (Most Recent Fiscal Quarter) | 1.63 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 1.15 |
| Inventory Turnover (Trailing 12 Months) | 2.05 |
| Book Value per Share (Most Recent Fiscal Quarter) | $0.31 |
| Earnings per Share (Most Recent Fiscal Quarter) | $-0.04 |
| Earnings per Share (Most Recent Fiscal Year) | $-0.11 |
| Diluted Earnings per Share (Trailing 12 Months) | $-0.10 |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Medical Devices |
| Common Shares Outstanding | 191.16M |
| Free Float | 184.66M |
| Market Capitalization | $252.33M |
| Average Volume (Last 20 Days) | 1.38M |
| Beta (Past 60 Months) | 1.55 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 3.40% |
| Percentage Held By Institutions (Latest 13F Reports) | 78.37% |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |